CATX 8-K
Perspective Therapeutics, Inc. (CATX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On October 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
PERSPECTIVE THERAPEUTICS, INC. |
|
|
|
|
Date: |
October 1, 2026 |
By: |
/s/ Joel Sendek |
|
|
|
Joel Sendek |
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology
Designed to be the Most Potent Payload in Targeted Oncology
Three Independent Clinical-Stage Programs, Each Against a Distinct Target with Data in 2026
Deep Leadership Across Radiopharmaceutical and Drug Development
The Perspective Story in Four Parts
Radiopharmaceutical Therapy: A Category Still Early in Its Adoption Curve
Targeted Delivery of Payloads is Transforming Oncology Therapy
$45 Billion+ Addressable Market, Already Generating Blockbuster Radiopharmaceutical Revenue
VMT-α-NET, VMT01, PSV359, and PSV594 Address a Combined $45B+ Solid Tumor Market
Pipeline in Depth: The Data Behind Each Program
Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
Neuroendocrine Tumors VMT-α-NET
SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need
VMT-α-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
Ongoing Phase 1/2a to Establish Broad Therapeutic Window for VMT-α-NET
Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis
VMT-α-NET Best Response Deepens Over Time
VMT-α-NET Responses Deepen Over Time
Spider Plot of Tumor Change Over Time by Patient
VMT-⍺-NET: Durable Disease Control Across All Doses
Best-in-class Safety Profile1
Blood Creatinine During Follow-up for All Patients Treated (n=68)
VMT-α-NET ’s Compelling Profile Supports Potential Registration Study at Current Dose Level
Melanoma VMT01
Checkpoint Inhibitors Transformed Melanoma Care but Still Leave Many Behind
VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma
Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma
Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01
Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)
VMT01 Clinical Data Support Further Development
PSV359 Advanced Solid Tumors
PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors
FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential
Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors
PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent
CCK2R81 a potential first-in-class in selected solid tumors
Perspective’s CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa
Platform and Manufacturing
Optimizing Structural Chemistry:
Choosing the Right Isotope
Not All ²¹²Pb Programs Are Created Equal
Advancing a Theranostic Approach:
Direct-to-Hospital Delivery through Integrated Isotope Production
Reaching the Largest Addressable Market with Regional Manufacturing
Financial Strength and IP
Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain
A Decade of Deliberate, End-to-End Engineering
Built Over a Decade - The Platform Is Built; Pipeline Advancing
Abbreviations
APPENDIX – Backup Slides
Investment thesis
Engineering the Alpha Advantage in Targeted Oncology
Optimizing the Entire System for Targeted Oncology
Advancing a Diverse 212Pb-Based Oncology Portfolio
Market opportunity
Solid Tumors are an Attractive Market for Radiopharmaceuticals
NETs Trials
2L+ Metastatic Melanoma Trials
VMT-α-NET
VMT-⍺-NET: Designed with Broad Therapeutic Window
VMT-α-NET Dosimetry: Independent Investigator Findings
VMT-α-NET Dosimetry: Highlights from the Phase 1 Study
VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis
Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment
VMT01
ICI Combo Rationale: Strong Synergy with VMT01 in Melanoma
Metastatic Melanoma: Confirmed Partial Response after 2 Cycles of [212Pb]VMT01
PSV359
PSV359 is Active Against FAP-α Expression on Tumor and on Stroma
Platform and Manufacturing
Construct Designed for Better Clinical Outcome
212Pb Uniquely Suited for Combination with Immune Checkpoint Inhibitors
Kinetics Matter: 212Pb Hits Hard and Fast for Strong Activity with Less Systemic Exposure
On-Demand Fulfillment at Regional Sites for Finished Product Delivery
Ideal for Regional Manufacturing
Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product
IP protection
